The US Food and Drug Administration granted accelerated approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive non-small cell lung cancer and pancreatic ductal adenocarcinoma (PDAC). Here, ERBB3 is linked to non-small cell lung carcinoma.